Pezalla Edmund J, Rosen David, Erensen Jennifer G, Haddox J David, Mayne Tracy J
Bioconsult, LLC, Wethersfield.
Purdue Pharma L.P., Stamford, CT.
J Pain Res. 2017 Feb 14;10:383-387. doi: 10.2147/JPR.S129553. eCollection 2017.
Opioid abuse and misuse in the USA is a public health crisis. The use of prescription opioid analgesics increased substantially from 2002 through 2010, then plateaued and began to decrease in 2011. This study examined prescriptions of branded and generic immediate- and extended-release opioid analgesics from 1992 to 2016. This was juxtaposed against state and federal policies designed to decrease overutilization and abuse, as well as the launch of new opioid products, including opioids with abuse-deterrent properties (OADPs). The data indicate that these health policies, including the utilization and reimbursement of OADPs, have coincided with decreased opioid utilization. The hypothesis that OADPs will paradoxically increase opioid prescribing is not supported.
美国的阿片类药物滥用和误用是一场公共卫生危机。从2002年到2010年,处方阿片类镇痛药的使用大幅增加,随后趋于平稳,并于2011年开始下降。本研究调查了1992年至2016年品牌和非专利即释及缓释阿片类镇痛药的处方情况。这与旨在减少过度使用和滥用的州和联邦政策,以及新阿片类产品的推出,包括具有滥用威慑特性(OADP)的阿片类药物形成对比。数据表明,这些卫生政策,包括OADP的使用和报销,与阿片类药物使用的减少相吻合。OADP会反常地增加阿片类药物处方的假设不成立。